Novadip Biosciences to present data at 17th Annual Meeting of the International Federation for Adipose Therapeutics and Science
December 4, 2019
Mont-Saint Guibert, Belgium, 4 December 2019: Novadip Biosciences (“Novadip” or “the company”), a clinical-stage biopharmaceutical company leveraging its unique tissue regeneration technology platform to generate multiple product candidates, announces that it is presenting data in a series of presentations at the 17th Annual Meeting of the International Federation for Adipose Therapeutics and Science (IFATS) taking place in Marseille, France, from 4-7 December 2019.
Dr Denis Dufrane, Chief Scientific Officer and co-founder, Novadip, commented: “The findings that will be presented at IFATS highlight the capabilities of Novadip’s 3-dimensional, scaffold-free extracellular matrix (ECM) technology platform utilizing adipose-derived stem cells (ASCs) to generate product candidates to address critical size bone and skin reconstruction, as well as our manufacturing capabilities and expertise. We look forward to progressing our clinical programmes and generating further data in support of our unique platform as we look to address hard and soft tissue reconstruction for patients who have limited or no treatment options.”
Novadip will deliver five oral presentations and one video presentation. Details of the presentations and short summaries are below.
Genetic stability assessment in bone tissue-engineered products
Céline Pierard, oral presentation #8 (abstract 1395), 5 December 2019, 8:38 am CET
The presentation will discuss the different analytical approaches to predict the genetic behavior over the entirety of the manufacturing process for the company’s product candidates for bone reconstruction.
A scaffold-free graft for large critical size bone defect: preclinical evidence to clinical proof of concept
Sophie Veriter, video presentation #V5 (abstract 1363), 5 December 2019, 2:48 pm CET
The session will discuss how the scaffold-free 3D-graft (comprised of ASCs) plays a major role in promoting ASCs engraftment and to induce osteogenesis in a fibrotic environment and promote bone fusion in a critical-sized bone defect.
The in vivo immunogenicity of a human 3D scaffold-free tissue-engineered product for bone reconstruction: a xenogenic model
Gaëtan Thirion, oral presentation #30 (abstract 1382), 5 December 2019, 4:30 pm CET
Detail will be provided on how the human scaffold-free 3D approach, in a xenogenic model, can elicit a specific anti-human immune response but can maintain the potential of in vivo osteogenicity.
An allogenic 3D scaffold-free tissue-engineered product for deep thickness skin regeneration: in vitro development to in vivo proof of concept
Sophie Veriter, oral presentation #88 (abstract 1317), 6 December 2019, 5:50 pm CET
The presentation will discuss how the scaffold-free approach with the allogenic 3D-graft (derived from ASCs) demonstrated safety and efficacy in a stringent xenogenic model of hyperglycemic and ischemic deep-thickness wound.
Allogenic 3D scaffold-free tissue-engineered product for deep thickness skin regeneration: in vitro characterization and in vivo biocompatibility
Valérie Lebrun, oral presentation #90 (abstract 1341), 6 December 2019, 6:06 pm CET
The presentation will provide an overview of how the allogenic scaffold-free 3D-graft improves ASC bioactivity for the angiogenesis and in vivo remodelling by the specific ECM-proteins of wound healing.
Monitoring of cell culture conditions and early prediction of the quality of an osteogenic cell-based medicinal product
Anaïs Namur, oral presentation #136 (abstract 1392), 7 December 2019, 2:44 pm CET
The session will describe how cellular metabolism was studied throughout the company’s manufacturing process to better understand the physiology of the proliferative and differentiated cells and subsequently develop predictive tests focused on critical attributes of the final product.
Novadip has developed a unique tissue regeneration platform capable of generating multiple product classes to transform the lives of patients with limited or no effective treatment options.